Skip to main content

Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals.

Publication ,  Journal Article
Justice, AC; Gordon, KS; Skanderson, M; Edelman, EJ; Akgün, KM; Gibert, CL; Lo Re, V; Rimland, D; Womack, JA; Wyatt, CM; Tate, JP; VACS Project Team,
Published in: AIDS
March 27, 2018

BACKGROUND: HIV-positive individuals (HIV+) on antiretrovirals commonly take enough other medications to cross a threshold for polypharmacy but little is known about associated outcomes. We asked whether non-antiretroviral polypharmacy is associated with hospitalization and mortality and whether associations differ by HIV status. METHODS: Data on HIV+ and uninfected individuals in the US Veterans Affairs Healthcare System were analyzed. Eligible HIV+ were on antiretrovirals with suppressed HIV-1 RNA and uninfected individuals received at least one medication. We calculated average non-antiretroviral medication count for fiscal year 2009. As there is no established threshold for non-antiretroviral polypharmacy, we considered more than two and at least five medications. We followed for hospitalization and mortality (fiscal year 2010-2015), adjusting for age, sex, race/ethnicity and VACS Index. RESULTS: Among 9473 HIV+ and 39 812 uninfected individuals respectively, non-antiretroviral polypharmacy was common (>2: 67, 71%; ≥5: 34, 39%). VACS Index discriminated risk of hospitalization (c-statistic: 0.62, 0.60) and mortality (c-statistic: 0.72, 0.70) similarly in both groups. After adjustment, more than two (hazard ratio 1.51, 95% CI 1.46-1.55) and at least five non-antiretrovirals (hazard ratio 1.52, 95% CI 1.49-1.56) were associated with hospitalization with no interaction by HIV status. Risk of mortality associated with more than two non-antiretrovirals interacted with HIV status (P = 0.002), but not for at least five (adjusted hazard ratio 1.43, 95% CI 1.36-1.50). For both groups and both outcomes, average medication count demonstrated an independent, dose response, association. CONCLUSION: Neither severity of illness nor demographics explain a dose response, association of non-antiretroviral polypharmacy with adverse health outcomes among HIV+ and uninfected individuals.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

March 27, 2018

Volume

32

Issue

6

Start / End Page

739 / 749

Location

England

Related Subject Headings

  • Young Adult
  • Virology
  • Veterans
  • United States
  • Survival Analysis
  • Prospective Studies
  • Polypharmacy
  • Middle Aged
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Justice, A. C., Gordon, K. S., Skanderson, M., Edelman, E. J., Akgün, K. M., Gibert, C. L., … VACS Project Team, . (2018). Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS, 32(6), 739–749. https://doi.org/10.1097/QAD.0000000000001756
Justice, Amy C., Kirsha S. Gordon, Melissa Skanderson, Eva Jennifer Edelman, Kathleen M. Akgün, Cynthia L. Gibert, Vincent Lo Re, et al. “Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals.AIDS 32, no. 6 (March 27, 2018): 739–49. https://doi.org/10.1097/QAD.0000000000001756.
Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün KM, Gibert CL, et al. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS. 2018 Mar 27;32(6):739–49.
Justice, Amy C., et al. “Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals.AIDS, vol. 32, no. 6, Mar. 2018, pp. 739–49. Pubmed, doi:10.1097/QAD.0000000000001756.
Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün KM, Gibert CL, Lo Re V, Rimland D, Womack JA, Wyatt CM, Tate JP, VACS Project Team. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS. 2018 Mar 27;32(6):739–749.

Published In

AIDS

DOI

EISSN

1473-5571

Publication Date

March 27, 2018

Volume

32

Issue

6

Start / End Page

739 / 749

Location

England

Related Subject Headings

  • Young Adult
  • Virology
  • Veterans
  • United States
  • Survival Analysis
  • Prospective Studies
  • Polypharmacy
  • Middle Aged
  • Male
  • Humans